Concepts (124)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antigens, Surface | 2 | 2014 | 295 | 0.900 |
Why?
|
| Hypersensitivity | 2 | 2023 | 216 | 0.700 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2014 | 1033 | 0.660 |
Why?
|
| Allergens | 3 | 2023 | 247 | 0.620 |
Why?
|
| Antigens, CD1 | 2 | 2014 | 49 | 0.610 |
Why?
|
| Dendritic Cells | 2 | 2014 | 1085 | 0.600 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2020 | 118 | 0.600 |
Why?
|
| Paramyxoviridae Infections | 2 | 2014 | 86 | 0.590 |
Why?
|
| Glycoproteins | 2 | 2014 | 747 | 0.460 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2014 | 427 | 0.430 |
Why?
|
| Graft Survival | 1 | 2015 | 1062 | 0.400 |
Why?
|
| Lung Transplantation | 6 | 2011 | 359 | 0.380 |
Why?
|
| Asthma | 2 | 2020 | 871 | 0.380 |
Why?
|
| Kidney Transplantation | 1 | 2015 | 755 | 0.340 |
Why?
|
| Cytokines | 3 | 2014 | 2809 | 0.320 |
Why?
|
| Disease Management | 1 | 2014 | 1052 | 0.320 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 960 | 0.300 |
Why?
|
| Thrombomodulin | 2 | 2014 | 30 | 0.240 |
Why?
|
| Bronchiolitis Obliterans | 5 | 2011 | 74 | 0.230 |
Why?
|
| Dermatitis, Atopic | 1 | 2023 | 47 | 0.220 |
Why?
|
| Drug Hypersensitivity | 1 | 2023 | 128 | 0.210 |
Why?
|
| Arachis | 1 | 2021 | 65 | 0.200 |
Why?
|
| Peanut Hypersensitivity | 1 | 2021 | 67 | 0.190 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2020 | 79 | 0.180 |
Why?
|
| Ganciclovir | 2 | 2008 | 174 | 0.160 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2017 | 32 | 0.150 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2017 | 219 | 0.140 |
Why?
|
| Vaccines, Synthetic | 1 | 2017 | 355 | 0.140 |
Why?
|
| Epitopes | 1 | 2017 | 685 | 0.130 |
Why?
|
| Macrophages, Alveolar | 1 | 2014 | 67 | 0.130 |
Why?
|
| Tissue and Organ Procurement | 2 | 2015 | 233 | 0.120 |
Why?
|
| Metapneumovirus | 1 | 2014 | 58 | 0.120 |
Why?
|
| Cytomegalovirus Infections | 2 | 2008 | 462 | 0.120 |
Why?
|
| Respiratory Tract Infections | 2 | 2009 | 437 | 0.120 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2014 | 48 | 0.120 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2014 | 171 | 0.120 |
Why?
|
| Expert Testimony | 1 | 2014 | 90 | 0.110 |
Why?
|
| Europe | 1 | 2014 | 649 | 0.100 |
Why?
|
| Treatment Failure | 1 | 2015 | 1391 | 0.100 |
Why?
|
| Vaccination | 1 | 2017 | 1123 | 0.100 |
Why?
|
| Child | 6 | 2023 | 29154 | 0.100 |
Why?
|
| Reoperation | 1 | 2015 | 1382 | 0.100 |
Why?
|
| Antiviral Agents | 2 | 2008 | 1230 | 0.100 |
Why?
|
| Clarithromycin | 1 | 2011 | 119 | 0.090 |
Why?
|
| Databases, Factual | 2 | 2015 | 2218 | 0.090 |
Why?
|
| Interferon-alpha | 1 | 2014 | 889 | 0.090 |
Why?
|
| Heart-Lung Transplantation | 1 | 2009 | 24 | 0.090 |
Why?
|
| Hepatitis B Antibodies | 1 | 2009 | 58 | 0.090 |
Why?
|
| Consensus | 1 | 2014 | 978 | 0.090 |
Why?
|
| Humans | 17 | 2023 | 261506 | 0.080 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 1688 | 0.080 |
Why?
|
| Cells, Cultured | 2 | 2014 | 5637 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 1085 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 4298 | 0.080 |
Why?
|
| Flow Cytometry | 1 | 2014 | 3033 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 6207 | 0.080 |
Why?
|
| Time Factors | 4 | 2015 | 12926 | 0.080 |
Why?
|
| Graft Rejection | 2 | 2009 | 834 | 0.080 |
Why?
|
| United States | 2 | 2015 | 15433 | 0.070 |
Why?
|
| Lung Diseases, Fungal | 1 | 2008 | 124 | 0.070 |
Why?
|
| Adult | 8 | 2014 | 77950 | 0.070 |
Why?
|
| Opportunistic Infections | 1 | 2008 | 223 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 4988 | 0.070 |
Why?
|
| Precision Medicine | 1 | 2014 | 1154 | 0.070 |
Why?
|
| Age Factors | 1 | 2015 | 5377 | 0.070 |
Why?
|
| Bronchoscopy | 1 | 2008 | 474 | 0.070 |
Why?
|
| Tissue Donors | 1 | 2009 | 769 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 2992 | 0.060 |
Why?
|
| Adolescent | 5 | 2021 | 31252 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2021 | 16273 | 0.060 |
Why?
|
| Skin Pigmentation | 1 | 2023 | 47 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 2403 | 0.060 |
Why?
|
| Lung | 1 | 2014 | 3151 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 4320 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2014 | 4078 | 0.060 |
Why?
|
| Erythema | 1 | 2023 | 52 | 0.060 |
Why?
|
| Penicillins | 1 | 2023 | 143 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2015 | 6869 | 0.050 |
Why?
|
| Risk Factors | 3 | 2015 | 17523 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2015 | 8223 | 0.050 |
Why?
|
| Omalizumab | 1 | 2020 | 26 | 0.050 |
Why?
|
| Desensitization, Immunologic | 1 | 2021 | 94 | 0.050 |
Why?
|
| Young Adult | 3 | 2015 | 21445 | 0.050 |
Why?
|
| Pneumonia | 3 | 2014 | 751 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2013 | 7226 | 0.050 |
Why?
|
| Male | 8 | 2015 | 123000 | 0.050 |
Why?
|
| Immunoglobulin E | 1 | 2020 | 163 | 0.050 |
Why?
|
| Infant | 1 | 2015 | 13310 | 0.040 |
Why?
|
| Female | 8 | 2015 | 141928 | 0.040 |
Why?
|
| Postoperative Complications | 3 | 2009 | 5542 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2015 | 37905 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 1544 | 0.040 |
Why?
|
| Skin | 1 | 2023 | 1259 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 544 | 0.040 |
Why?
|
| Animals | 2 | 2017 | 59536 | 0.030 |
Why?
|
| Transplantation, Homologous | 2 | 2011 | 2843 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 423 | 0.030 |
Why?
|
| Airway Obstruction | 1 | 2014 | 261 | 0.030 |
Why?
|
| Virus Replication | 1 | 2014 | 709 | 0.020 |
Why?
|
| Follow-Up Studies | 3 | 2011 | 14889 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 2314 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 3251 | 0.020 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2008 | 53 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 8865 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 4367 | 0.020 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2009 | 157 | 0.020 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2009 | 158 | 0.020 |
Why?
|
| Syndrome | 1 | 2011 | 1351 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2008 | 543 | 0.020 |
Why?
|
| Hepatitis B | 1 | 2009 | 258 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2008 | 665 | 0.020 |
Why?
|
| Survival Rate | 2 | 2011 | 12221 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2009 | 9244 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2008 | 502 | 0.020 |
Why?
|
| Mycoses | 1 | 2009 | 386 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2008 | 717 | 0.010 |
Why?
|
| Middle Aged | 4 | 2011 | 86204 | 0.010 |
Why?
|
| Length of Stay | 1 | 2008 | 1900 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 7222 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 4938 | 0.010 |
Why?
|
| Aged | 3 | 2009 | 70117 | 0.010 |
Why?
|
| Incidence | 1 | 2009 | 5673 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2008 | 9180 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2008 | 32848 | 0.010 |
Why?
|